NASDAQ · SERVICES-MANAGEMENT CONSULTING SERVICES · LARGE CAP
Astrana Health, Inc. ASTH
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.2B
▲ 56.4% vs FY2024
EPS · FY25
$0.46
Dividend / sh · FY25
—
Payout · FY25
35%
ROE · FY25
3.0%
Net margin · FY25
0.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.2B
Revenue, FY2025 · full 16-year series below
Revenue
Net income
1 cents of every revenue dollar became profit this year.
Per share
USD 0.46
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
3.0%
Return on equity, FY2025
ROE
Operating margin2.5%
Net margin0.7%
Return on assets1.3%
Each USD of equity produced 3 cents of profit this year.
Returned to shareholders
USD 33.5M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 7.9M
Net buybacksUSD 25.6M
Share of profit148.9%
Consecutive raises—
USD 7.9M in dividends and USD 25.6M in buybacks — 149% of the year's profit, so the payout drew on cash built up earlier.
Growth
+35.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+40.6%
+35.9%
+53.4%
+56.4%
Net income
−20.7%
−9.8%
EPS, diluted
−22.5%
−14.6%
Returned to shareholders
+12.9%
−8.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+33.5%
Change, 10 years—
The share count grew 33% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.2B
total assets, end of FY2025
Total assetsUSD 2.2B
EquityUSD 779.3M
CashUSD 429.5M
Gross debtUSD 1.0B
Net debtUSD 609.3M
Current ratio1.40×
Net debt stands at 78% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
3.2
2.0
1.4
1.1
0.8
0.7
0.6
0.5
0.4
0.3
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.1
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EBITDA $B
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
0.0
0.1
0.0
0.1
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.46
0.90
1.29
0.99
1.52
1.01
0.39
0.29
0.90
0.41
−1.79
−0.37
−1.37
−0.27
−0.02
−0.01
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
35
9
102
31
45
136
437
164
40
233
·
·
·
·
·
·
ROE %
3.0
6.5
10.5
9.1
17.7
14.4
7.6
6.4
20.9
26.7
·
·
·
·
·
·
Shares out B
0.05
0.05
·
·
·
·
0.04
0.03
0.03
0.03
0.01
0.00
0.00
0.03
0.03
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
51 of 51
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed